🇺🇸 FDA
Patent

US 9248119

Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

granted A61KA61K31/426A61K9/0004

Quick answer

US patent 9248119 (Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors) held by Takeda Pharmaceuticals U.S.A., Inc. expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceuticals U.S.A., Inc.
Grant date
Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/426, A61K9/0004, A61K9/0053, A61K9/1629